RSS Feeds
Search

Press releases

Stay current with the latest press releases from within the industry.

Probiodrug's P93/01 in clinics for the treatment of type 2 diabetes

Release issued 25th February 2003

Probiodrug AG announced today that the company has concluded its first in man dosing study of P93/01, its lead candidate to be developed for the treatment of type 2 diabetes. P93/01 is one of a number of proprietary DP IV- inhibitor molecules which showed promising safety and efficacy in preclinical studies.

Probiodrug AG is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of diabetes, obesity and other serious medical conditions based on its detailed understanding of the actions of Dipeptidyl Peptidase IV and related enzymes.

Company details

If you want to find out more about the company visit Probiodrug profile.

Latest Probiodrug press releases

(25th June 2007) Probiodrug AG, Halle (Saale) Acquires Ingenium Pharmaceuticals AG (Munich)

(16th June 2006) Probiodrug Closes a EUR 10.6 Million (US$ 13.4 million) Financing Round

(6th July 2004) Probiodrug awarded a €1.9mio BioChancePlus grant

(18th June 2004) Prosidion and Probiodrug conclude metabolic deal

(16th December 2003) Probiodrug hosts Scientific Advisory Board December 12th & 13th

Related reports

Market Research Reports provided by reports.iptechex.com
Probiodrug AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Mar 2011 - 28 pages - $250
Diabetes Drug Discoveries 2009: what the future holds
Feb 2009 - 160 pages - $1,390
Hot Topics in Type 2 Diabetes: Complications and Comorbidities – Physician insight on diabetic complications, comorbidities and treatment
Aug 2011 - 55 pages - $5,700
Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetes
Jul 2011 - 92 pages - $7,600
Post ADA Diabetes Treatment Market Assessment
Jun 2008 - $2,500
Epidemiology: Diabetes in Australia - Despite government efforts to promote healthy lifestyles, the number of cases of diabetes in Australia is set to soar
Jun 2011 - 44 pages - $5,700
Tradjenta (linagliptin) - First Member of DPP - 4 Inhibitor Class to Be Approved by US FDA at One Dosage Strength
May 2011 - 7 pages - $500
Epidemiology: Diabetes in India - a country faced with a mammoth diabetes epidemic
Mar 2011 - 43 pages - $5,700
Hot Topics in Type 2 Diabetes: Physician Perceptions of Insulin - Physician survey provides insights into insulin usage and needs
Jun 2011 - 54 pages - $5,700
Prescribing Influences: Type 2 Diabetes – Opportunities in type 2 diabetes for drugs with both safety and efficacy
Sep 2011 - 76 pages - $3,800
More Related Market Research Reports >>>

More Press Releases

Latest

Pharmalicensing and Bionow sign strategic marketing and member benefit agreement
Beacon Launch New Website
Beacon Launch Streptokinase
A New Therapeutic Approach to Treat Oral Mucositis Using Specific MMP Blockers in an Osmotically Active Solution.
VITRO-BIO Pharma

Most viewed

euroPLX Introduces Tool to Overcome Reject vs. Accept Dilemma in Partnering
Genesis Conference on target to exceed all previous years
Two papers on Neo-Penotran® Forte and Neo-Penotran® Forte-L have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004
Discovery and validation of 13 diabetes biomarkers to be commercialized
TDS® TESTOSTERONE EXCEEDS ANDROGEL® OUTCOMES

Related categories

Therapeutic target
Metabolism
Diabetes type I
Industry sector
Pharmaceutical

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us